metformin has been researched along with Retrolental Fibroplasia in 1 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin treatment did not change the extent of avascular areas at P17." | 1.42 | Anti-angiogenic effect of metformin in mouse oxygen-induced retinopathy is mediated by reducing levels of the vascular endothelial growth factor receptor Flk-1. ( Choi, JA; Joe, SG; Koh, JY; Yoon, YH, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Joe, SG | 1 |
| Yoon, YH | 1 |
| Choi, JA | 1 |
| Koh, JY | 1 |
1 other study available for metformin and Retrolental Fibroplasia
| Article | Year |
|---|---|
Anti-angiogenic effect of metformin in mouse oxygen-induced retinopathy is mediated by reducing levels of the vascular endothelial growth factor receptor Flk-1.
Topics: Angiogenesis Inhibitors; Animals; Blotting, Western; Cell Proliferation; Enzyme-Linked Immunosorbent | 2015 |